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Hepatic but not intestinal CYP3A4 displays
dose-dependent induction by efavirenz
in humans
Objective: The capacity of the non-nucleoside reverse transcriptase inhibitor efavirenz to induce either liver
CYP3A4 or intestinal CYP3A4, or both, as well as intestinal P-glycoprotein, was evaluated in healthy
volunteers during and after a 10-day treatment course with two different daily doses.
Methods: Cohorts of 12 healthy subjects were randomized (2:1) to receive either efavirenz or placebo orally for
10 days. The first cohort received 200 mg efavirenz and the second cohort received 400 mg efavirenz daily.
Liver CYP3A4 activity was evaluated on 9 different occasions with use of the erythromycin breath test
(ERMBT). Intestinal biopsy specimens were obtained before the first dose of efavirenz and on the day after
administration of the last dose to measure intestinal CYP3A4 and P-glycoprotein contents by immunoblot-
ting. Efavirenz plasma levels were measured by HPLC, and pharmacokinetic parameters were determined by
standard noncompartmental methods.
Results: Efavirenz significantly increased the mean ERMBT result in a dose- and time-dependent manner,
with a 55% mean induction at 400 mg and a 33% mean induction at 200 mg (P < .01, compared with placebo
for each treatment). The efavirenz AUC on day 10 correlated with the magnitude of induction (day 11/day
1 ERMBT ratio) when the two dose groups were combined (r  0.509; P  .04). In contrast, efavirenz
treatment had no detectable effect on intestinal CYP3A4 or P-glycoprotein.
Conclusions: Efavirenz is an inducer of liver CYP3A4 in healthy volunteers, and interpatient differences in
magnitude of induction is partly explained by variation in systemic drug exposure. However, efavirenz did
not appear to induce intestinal CYP3A4 or intestinal P-glycoprotein. These results suggest that drug inter-
actions caused by induction of CYP3A4 can be liver specific. (Clin Pharmacol Ther 2002;72:1-9.)
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is an extremely potent non-nucleoside reverse tran-
scriptase inhibitor that is widely used in the treatment
of patients with human immunodeficiency virus-1
(HIV-1) infection. It is essentially completely metabo-
lized in vivo and, in humans, 66% of the dose at 400
mg/day (5.7 mg/kg/day) has been recovered in urine as
the glucuronide conjugate of the 8-hydroxymetabolite
(Bristol-Myers Squibb, unpublished data, July 2000).
Both CYP3A4 and CYP2B6 have been implicated in
the 8-hydroxylation pathway by studies performed in
vitro (Bristol-Myers Squibb, unpublished data, July
2000). CYP3A4 is usually the major cytochrome P450
present in both liver and intestine in humans.1 CYP2B6
is present in the liver but has not been reported to be
present in the intestine.2
During initial preclinical studies, efavirenz was
noted to induce its own metabolism and to increase the
activities of liver CYP3A and CYP2B isoforms in rats
and rhesus monkeys (Bristol-Myers Squibb, unpub-
lished data, July 2000). Clinical observations also make
it likely that efavirenz induces CYP3A4 in humans.
Efavirenz has been shown to induce the metabolism of
methadone, a CYP3A4 substrate, in patients with HIV
infection, leading to a 60% decrease in methadone
systemic exposure and methadone withdrawal symp-
toms.3,4 In addition, efavirenz treatment results in a
decrease in the blood levels of indinavir, which is
consistent with CYP3A4 induction.5
Induction of CYP3A4 by most drugs appears to
involve binding to a receptor termed hPXR (also termed
SXR or PAR), resulting in transcriptional activation of
the CYP3A4 gene.6 The hPXR receptor also appears to
mediate induction of P-glycoprotein (MDR1 gene prod-
uct), a xenobiotic transport protein present in liver and
intestine involved in some drug interactions,7 and
CYP2B6.8 The hPXR receptor has been shown to be
present in enterocytes and presumably accounts for
induction of intestinal CYP3A4 and P-glycoprotein
when patients receive treatment with at least some
inducers of liver CYP3A4.7
If induction of CYP3A4 by efavirenz does occur and
is mediated by hPXR, we believed that efavirenz would
likely induce CYP3A4 (and P-glycoprotein) in both the
liver and small intestine in vivo. To test this hypothesis,
efavirenz at 2 dose levels or placebo was administered
to 24 healthy adults for 10 days. Liver CYP3A4 activity
was measured on multiple occasions with use of the
14C-erythromycin breath test (14C-ERMBT).9 Intestinal
CYP3A4 and P-glycoprotein expression (in small in-
testinal biopsy specimens) before and after a 10-day
drug treatment was also measured. As a secondary aim,
we examined whether variation in liver CYP3A4, in-
testinal CYP3A4, or intestinal P-glycoprotein levels
correlated with variations in pharmacokinetic parame-
ters of systemic exposure to efavirenz.
METHODS
Subjects
Eligible subjects were nonsmokers between 18 and
50 years old and were within 15% of their ideal body
weights. No subjects had taken any prescription or
over-the-counter medications for 30 days, and they had
not consumed grapefruit or grapefruit juice within 1
week before the start of the study. No subjects had any
significant medical problems or laboratory test abnor-
malities. All subjects were screened for medical prob-
lems by history and physical examination, 12-lead elec-
trocardiogram, hepatitis B, C, and A antibodies, HIV
antibodies, urine drug screen, complete blood count,
serum electrolytes, liver chemistries, and prothrombin
time.
Experimental design
This was a single-center, double-blind, randomized,
placebo-controlled study approved by the University of
Michigan Institutional Review Board (Ann Arbor,
Mich). The study required 2 separate admissions to the
General Clinical Research Center. The first admission
was for approximately 36 hours (2 nights) and occurred
the day before the start of the study (day 0). The
subjects were entered in 2 cohorts of at least 12 subjects
each. Subjects were randomized within each cohort to
receive either efavirenz or placebo in a 2:1 ratio, re-
spectively. The dose levels of efavirenz studied were
200 mg (cohort 1) and 400 mg (cohort 2). The 200-mg
dose was studied first and the data analyzed before we
proceeded with the 400-mg daily cohort. Within each
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cohort, 8 subjects were randomized to receive efavirenz
and 4 subjects were randomized to receive matching
placebo. The administration of any concomitant medi-
cation was prohibited during the entire study, starting 2
weeks before day 0 and extending to the end of the
subject’s participation (day 32). Alcohol- and caffeine-
containing foods and beverages were prohibited begin-
ning 48 hours before dose administration on day 1 and
day 10 and throughout each in-hospital period. Subjects
were to refrain from excess physical exertion through-
out the study duration and from lying down during the
first 5 hours after drug intake on day 1 and day 10.
After an initial screening visit, subjects were admit-
ted to the General Clinical Research Center on day 0 of
the study. They underwent endoscopy to obtain biopsy
samples from the small bowel for measurements of
CYP3A4 and P-glycoprotein protein concentrations at
baseline (day 0) and again after 10 days of drug inges-
tion (day 11). Subjects then began treatment with pla-
cebo, 200 mg/day efavirenz, or 400 mg/day efavirenz
for 10 days (day 1 to day 10 of the study), receiving
each dose (efavirenz or placebo) with 240 mL water.
An indwelling venous catheter was placed in a vein of
an arm of each subject for collecting blood samples and
administration of the intravenous ERMBT. After an
8-hour overnight fast, 5 mL blood was drawn (day 1
and day 10) before dosing and at 2, 3, 4, 5, 8, 12, and
24 hours after the first and last dose of the study drug
for determination of efavirenz oral pharmacokinetics.
The volunteers were discharged after they took their
second doses on day 2 of the study. Additional blood
samples were drawn on days 4 and 7. Liver CYP3A4
activity was measured with the ERMBT before the first
dose of the drug on day 1 (baseline) and again on days
2, 4, 7, 11 (after the 24-hour blood sample), 12, 15, 18,
and 32 of the study. The subjects were readmitted on
day 9 for the 24-hour pharmacokinetic study with the
final dose of efavirenz (according to the same design as
day 1) and for repeated performance of small bowel
biopsies on day 11. Subjects were discharged from the
General Clinical Research Center the following morn-
ing (day 12). They returned to the outpatient clinic on
days 15 (120 hours after dosing), 18 (192 hours after
dosing), and 32 (528 hours after dosing) to receive the
scheduled ERMBT.
Pharmacokinetic analysis
Plasma was separated from blood by centrifugation
at 3000 rpm for 15 minutes and then transferred to
labeled polypropylene cryotubes and stored at 20°C
pending analysis. Efavirenz plasma concentrations
were determined by HPLC with ultraviolet detection,
using minor modifications to a previously validated and
published method.10 The assay had a limit of detection
of 0.05 mol/L. Quality control samples at different
concentrations of efavirenz had coefficients of variation
for precision and accuracy of 10% for all concentra-
tions examined. The peak plasma concentration (Cmax),
time to reach Cmax (tmax), and trough plasma level
(Cmin) were determined directly from the plasma con-
centration versus time data. Total area under the ob-
served plasma concentration–time curve (AUC) was
calculated by use of the linear trapezoidal method. The
apparent oral clearance (CL/F) was calculated by di-
viding the efavirenz dose by the AUC. The terminal
elimination rate constant (n) was determined by the
slope of the log-linear terminal phase of the curve (ie,
last 3 concentration–time points). The drug half-life
(t1/2) was calculated as n/0.693.
Erythromycin breath test
The ERMBT was administered as described previ-
ously.9 In brief, a baseline breath sample was collected,
3 Ci (0.074 mmol, 0.0543 mg) of [14C-N-methyl]-
erythromycin (Metabolic Solutions Inc, Nashua, NH)
was injected intravenously, and a single breath collec-
tion was made 20 minutes later. Breath test results were
expressed as the percentage of administered 14C that
was exhaled during the first hour after the injection of
erythromycin, estimated from the rate of 14CO2 exha-
lation at 20 minutes as recently modified.11
Intestinal CYP3A4 and P-glycoprotein
measurements
Endoscopy. Each subject underwent upper intestinal
endoscopy after a 4-hour postbreakfast fast. While un-
der conscious sedation induced by a combination of
intravenous midazolam and meperidine (INN, pethi-
dine), a video-endoscope was passed into the second
portion of the duodenum where 5 mucosal biopsy spec-
imens were obtained. The biopsy specimens from each
set were immediately placed in an ice-cold solution of
0.05 mol/L Tris hydrochloride, 20% glycerol, 2
mmol/L ethylenediaminetetraacetic acid, and 1 mmol/L
phenylethylsulfonyl fluoride, homogenized in a glass
dounce, and snap frozen in liquid nitrogen. The samples
were stored at 80°C pending analysis.
CYP3A4, CYP2B6, and P-glycoprotein immuno-
blotting. Protein concentrations were determined by
immunoblotting as previously described,12-15 with mi-
nor modifications. Proteins (15 g of the whole biopsy
homogenate) were separated with use of a 7% poly-
acrilamide/0.1% sodium dodecyl sulfate gel and trans-
ferred to nitrocellulose. The blots were blocked for 1
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hour in Tris-buffered saline solution that contained
0.3% Tween 20 (Sigma Chemical Co, St Louis, Mo)
and Carnation 5% nonfat dry milk (Nestle´, Vevey,
Switzerland). After all antibody incubations were com-
pleted, the blots were developed with a chemilumines-
cence kit. Optical densities were converted to quanti-
tative numbers by comparison to slot blots of serial
dilutions of purified CYP3A4 protein that had been
processed simultaneously with the immunoblots. To
obtain accurate measures of P-glycoprotein and
CYP3A4, immunoblots were repeated a total of 4 to 7
times. Final values were calculated from the arithmetic
mean of all of the runs, with any outlying points (great-
er than 2 standard deviations from the mean for that
sample) omitted. Biopsy levels of CYP3A4 and
P-glycoprotein were expressed as a ratio with the villin
level of the same sample (ie, CYP3A4/villin and P-
glycoprotein/villin), as described previously.12-15 For
the sake of simplicity, we have termed the ratios en-
terocyte concentrations. The mean coefficients of vari-
ation for the enterocyte concentrations of CYP3A4 and
P-glycoprotein were 27% (SD, 17%) and 38% (SD,
17%), respectively.
The intestinal homogenates were also blotted for
CYP2B6 with the method described earlier, except that
separation was performed with 9% polyacrylamide in-
stead of 7% polyacrylamide. The filters were then in-
cubated with WB-2B6-PEP, a rabbit immunoglobulin
G monoclonal primary antibody specific for human
CYP2B6 proteins (Gentest Corporation, Woburn,
Mass), and goat anti-rabbit secondary antibodies con-
jugated with peroxidase (Zymed, South San Francisco,
Calif). Optical densities were converted to quantitative
numbers by comparison to slot blots of serial dilutions
of purified CYP2B6 protein that had been processed
simultaneously with the immunoblots.
Statistical analysis
Statistical analysis of the data was performed with
SAS software (version 6.12, SAS Institute Inc, Cary,
NC). A sample size of 8 subjects for each treatment
group was used to have a greater than 80% power to
detect a 50% difference in the ERMBT results (with
  .05 as the level of significance), assuming a stan-
dard deviation of 25% and using a 2-sided paired t test.
Values for efavirenz AUC, Cmax, Cmin, and dose were
log-transformed to normalize their distribution for sta-
tistical analysis. ERMBT differences among the 3 treat-
ments were assessed with use of a 1-way ANOVA
model at each scheduled assessment time. Pairwise
differences between treatments were assessed with the
Fisher least significant difference. A repeated-measure
ANOVA was performed to assess differences among
treatments over time. To determine whether an ordered
difference among treatment groups was present, the
Jonckheere-Terpstra test, a nonparametric test, was per-
formed. Intestinal biopsy measurements of CYP3A4
and P-glycoprotein were analyzed analogously to the
ERMBT results without a repeated-measure analysis.
The relationships between efavirenz CL/F, intestinal
CYP3A4 content, intestinal P-glycoprotein content,
and hepatic CYP3A4 activity (ERMBT) were exam-
ined with use of Spearman’s correlation coefficient.
RESULTS
Demographic characteristics
Twenty-four healthy volunteers (1 woman and 23
men) completed the study; 1 subject was discontinued
because of a protocol violation. Twenty-one (84%)
subjects were white, 1 (4.0%) was black, 2 (8%) were
Asian or Pacific islanders, and 1 (4%) was Hispanic.
Mean age of the subjects was 29.9 8.7 years (median,
27 years; age range, 19 to 49 years), with no difference
between groups. Eight subjects received 200 mg/day
efavirenz, 8 received 400 mg/day efavirenz, and 8
received placebo (4 in cohort 1 and 4 other in cohort 2).
Pharmacokinetics
Concentration versus time profiles of the 2 efavirenz
dosing regimens on day 1 and day 10 are presented in
Fig 1. Table I summarizes the main pharmacokinetics
parameters for the 2 dosing regimens on day 1 and day
10. The mean Cmax, Cmin, and AUC, were significantly
greater (P  .05) in the higher-dose group than in the
low-dose group. However, CL/F and t1/2 values were
not significantly different between the 2 dose regimens.
Induction of liver CYP3A4 by efavirenz
Hepatic CYP3A4 activity (ie, ERMBT) was signifi-
cantly increased (P  .05) by efavirenz compared with
placebo. Induction of liver CYP3A4 was significantly
higher (P  .05) with the 400-mg dosing regimen than
with the 200-mg dosing regimen on day 7 and from day
12 to day 32 (Table II). In the higher-dose group,
induction occurred as early as day 4, and dissipation of
induction was observed by day 32 (400-mg dose
group), 21 days after the last efavirenz dose. In the
200-mg group, the induction of liver CYP3A4 by efa-
virenz was evident on day 11 and had dissipated on day
18. In addition, there was a significant ordered differ-
ence (P  .05) between the treatment groups (higher
ERMBT ratio associated with higher efavirenz dose
level) for days 4 to 18 (Table II). Taken together, these
results indicate a time- and dose-dependent induction of
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liver CYP3A4 activity by efavirenz, as assessed by the
ERMBT.
Effects of efavirenz on intestinal variables
Enterocyte concentrations of P-glycoprotein and
CYP3A4 on day 0 (before the first dose of efavirenz)
and day 11 (24 hours after the last dose of efavirenz), as
assessed by immunoblots of the biopsy homogenates,
are presented in Fig 2, A and B, respectively. The
geometric mean (ratio) of enterocyte CYP3A4 concen-
trations on day 11 and day 0 was 1.130 (95% confi-
dence interval [CI], 0.865 to 1.476) for the placebo
group, 1.124 (95% CI, 0.899 to 1.405) for the 200-mg
efavirenz group, and 1.016 (95% CI, 0.840 to 1.228) for
the 400-mg efavirenz group. Likewise, the geometric
mean (ratio) of enterocyte P-glycoprotein concentra-
tions on day 11 and day 0 was 1.138 (95% CI, 0.895 to
1.447) for the placebo group, 1.145 (95% CI, 0.888 to
1.476) for the 200-mg efavirenz group, and 1.057 (95%
CI, 0.893 to 1.250) for the 400-mg efavirenz group.
None of the pairwise differences between treatment
groups were significant for either enterocyte concentra-
tion of CYP3A4 or enterocyte concentration of
P-glycoprotein. The Jonckheere-Terpstra test did not
show a significant ordered difference between the treat-
ment groups for either enterocyte concentration of
CYP3A4 or P-glycoprotein.
When all subjects were analyzed together, there was
a positive correlation between enterocyte concentra-
tions of CYP3A4 determined on day 0 and the concen-
tration determined on day 11 (r  0.615; P  .001;
Spearman rank correlation). Likewise, there was a pos-
itive correlation between enterocyte concentrations of
P-glycoprotein determined on day 0 and day 10 (r 
0.54; P  .01; Spearman rank correlation). As expect-
ed,13,14 the ERMBT result on day 1 was not correlated
to either intestinal CYP3A4 or P-glycoprotein concen-
trations on day 0 (rS0.17 and P NS for CYP3A4
and rS  0.01 and P  NS for P-glycoprotein; all
patients combined). The ERMBT result on day 11 was
also not correlated to either intestinal CYP3A4 or
P-glycoprotein concentrations on day 11 (rS  0.15
and P NS for CYP3A4 and rS0.017 and P NS
for P-glycoprotein; all patients combined). Efavirenz
CL/F was not correlated to enterocyte concentrations of
either CYP3A4 or P-glycoprotein (data not shown).
The intestinal biopsy homogenates were also probed
for immunoreactive CYP2B6 because this enzyme has
been implicated in efavirenz metabolism and because
CYP2B isoforms are induced in the livers of animals
treated with efavirenz (Bristol-Myers Squibb, unpub-
lished data, July, 2000). As shown in Fig 3, no CYP2B6
could be detected in human intestine either before or
after drug treatment. The lower limit of detection was
estimated to be 100 fmol of CYP2B6 protein per 20 g
of homogenate loaded.
Relationship between efavirenz pharmacokinetic
parameters and liver CYP3A4 activity
Because CYP3A4 was believed to be the major path-
way of efavirenz metabolism when this study was con-
ducted, the relationship between efavirenz pharmaco-
kinetic parameters and the ERMBT results was
examined. There was a trend for an inverse relationship
between efavirenz steady-state CL/F (day 10) and
ERMBT result (day 11) within each treatment group or
when all subjects were examined (r0.491 and P
.05 for all subjects). That is, the lower the efavirenz
CL/F, the higher the liver CYP3A4 activity (high
ERMBT value), contrary to expectation (see the “Dis-
cussion” section). In addition, the efavirenz AUC (day
10) was positively correlated (r  0.509 and P  .04
for all subjects) with the ERMBT ratio (day 11/day 1;
Fig 4). That is, the magnitude of liver CYP3A4 induc-
tion by efavirenz was related to the steady-state sys-
temic exposure (ie, AUC) of efavirenz when all sub-
jects were examined. However, this correlation was not
significant for each group taken individually (data not
shown).
Fig 1. Concentration versus time profiles of efavirenz
after single doses of 200 mg (diamonds) and 400 mg
(squares) on day 1 (solid lines) and on day 10 (broken
lines). Error bars represent the standard deviation (n 
8 in each group and for each point).
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DISCUSSION
This study was performed primarily to determine
whether efavirenz is an inducer of liver CYP3A4 in
humans in vivo and to characterize the time course of
this induction. We also wanted to determine whether
induction of liver CYP3A4 was accompanied by induc-
tion of intestinal CYP3A4 and P-glycoprotein, which
we expected if liver CYP3A4 induction by efavirenz
were mediated by hPXR.
Hepatic CYP3A4 activity, as measured by serial
ERMBTs, was clearly induced by efavirenz adminis-
tration (Table II). The magnitude of induction was
Table I. Pharmacokinetic parameters on days 1 and 10 and the day 10/day 1 ratio after dosing regimens of 200
mg and 400 mg efavirenz (n  8 subjects in each study group)
Pharmacokinetic
parameter Day 1* Day 10*
Cmax (mol/L)
Efavirenz, 200 mg 2.76 0.78 4.00 0.71†
Efavirenz, 400 mg 4.43 1.02‡ 6.98 1.47†‡
Cmin (mol/L)
Efavirenz, 200 mg 0.73 0.18 2.03 0.43†
Efavirenz, 400 mg 1.19 0.28 2.67 0.74†‡
AUC(0–24h) (mol/L  h)
Efavirenz, 200 mg 28.79 6.47 64.08 13.25†
Efavirenz, 400 mg 48.10 11.40‡ 92.59 17.23†‡
tmax (h)§
Efavirenz, 200 mg 3 (2–5) 3 (2–5)
Efavirenz, 400 mg 2.6 (2–5) 2.5 (2–5)
t1/2 (h)
Efavirenz, 200 mg — 67.2 44.0
Efavirenz, 400 mg — 77.9 29.4
CL/F (L/h)
Efavirenz, 200 mg — 10.25 1.98
Efavirenz, 400 mg — 14.15 2.93
Cmax, Peak plasma concentration; Cmin trough plasma level; tmax, time to reach Cmax; AUC(0–24h), area under the observed plasma concentration–time curve from
0 to 24 hours; t1/2, half-life; CL/F, oral clearance. Statistics are presented on nontransformed data, but data were log-transformed for analysis of Cmax, Cmin and AUC.
*Harmonic mean and pseudo standard deviation.
†Indicates a significant difference (P  .05) compared with day 1.
‡Indicates a significant difference (P  .05) compared with the 200-mg dose.
§Summarized with use of the median with minimum and maximum in parentheses.
Table II. Geometric mean ratio and 95% CI of the ERMBT (study day to baseline [ie, day 1] ratio) for the
placebo group and each efavirenz dosing regimen (n  8 subjects in each study group)
Study day
Placebo Efavirenz, 200 mg Efavirenz, 400 mg
Geometric mean 95% CI Geometric mean 95% CI Geometric mean 95% CI
Day 2 1.025 0.890–1.180 1.102 0.999–1.215 1.078 0.987–1.178
Day 4 1.161 1.040–1.296 1.210 1.048–1.397 1.381*† 1.174–1.625
Day 7 1.033 0.898–1.189 1.186 1.062–1.324 1.493*†‡ 1.272–1.752
Day 11 0.993 0.842–1.171 1.327* 1.127–1.563 1.546*† 1.370–1.744
Day 12 0.996 0.906–1.096 1.314* 1.186–1.456 1.550*†‡ 1.339–1.795
Day 15 0.958 0.848–1.082 1.161* 0.987–1.366 1.373*†‡ 1.214–1.553
Day 18 0.992 0.863–1.139 1.077 0.921–1.258 1.287*†‡ 1.166–1.422
Day 32 1.024 0.916–1.144 0.909 0.769–1.075 1.069‡ 0.962–1.187
95% CI, 95% Confidence interval; ERMBT, 14C-erythromycin breath test.
Differences among (1-way ANOVA) and between (Fisher least significant difference) dose groups were analyzed with use of the natural log-transformation of the ratio.
Note: Statistics are presented on non-transformed data but data were log-transformed for analysis of Cmax, Cmin and AUC.
*Indicates a significant difference (P  .05) compared with the placebo group.
†According to the Jonckheere-Terpstra test, statistically significant ordered difference between the dose groups (higher ERMBT ratio associated with increasing
efavirenz dose level).
‡Indicates a significant difference (P  .05) compared with the 200 mg efavirenz dose group.
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greater in the 400-mg treatment group than in the
200-mg treatment group, and it was time dependent.
The time-dependent changes in CYP3A4 activity prob-
ably largely mirrored the changes in systemic exposure
to the drug, given its mean t1/2 of 60 hours. Peak
systemic exposure (steady-state plasma levels) would
have been attained at around 10 days (5 t1/2 values), the
observed timing of peak induction. The dissipation in
induction also followed a time course consistent with
the expected decrease in plasma levels. It should be
noted that the magnitude of the mean change in the
ERMBT result (55%) with the 400-mg dose was less
than that observed with rifampin (INN, rifampicin)
treatment (up to 125%),10,16 indicating that the magni-
tude of induction produced by efavirenz is less.
We also found that subjects with the highest efa-
virenz AUC values tended to have the highest magni-
tudes of induction of CYP3A4 from baseline (Fig 4).
This supports the reasonable conclusion that the mag-
nitude of induction within an individual reflects in part
the integrated exposure of the liver of that individual to
the drug. This reinforces the importance of measure-
ment of parameters of systemic exposure in future
studies that examine potential genetic factors underly-
ing inducer responsiveness. Because systemic exposure
positively correlated with the ERMBT result, there was
an inverse correlation between hepatic CYP3A4 activ-
ity and efavirenz clearance. If CYP3A4 represented a
major pathway for efavirenz elimination (as was be-
lieved when these studies were undertaken), one would
expect a positive correlation between liver CYP3A4
activity and drug clearance. Our opposite finding is
therefore not compatible with the ability of liver
CYP3A4 to have a rate-limiting effect in the elimina-
tion of efavirenz. It now seems to be likely that
CYP2B6 may represent the more important pathway
for elimination of this drug in humans. We also rea-
soned that if intestinal metabolism or transport limited
efavirenz oral availability, there may exist inverse cor-
Fig 2. Intestinal content of P-glycoprotein (A) and
CYP3A4 (B) on days 0 and 11 after administration of
either placebo (squares), 200 mg efavirenz (diamonds),
or 400 mg efavirenz (triangles) once a day for 10 days.
Fig 3. Representative immunoblot of CYP2B6 in in-
testinal homogenates. Biopsy specimens of 1 subject in
each study group are shown before the first dose (D0)
and after the last dose (D11) of 200 mg efavirenz (lanes
1 and 2), 400 mg efavirenz (lanes 3 and 4), and placebo
(lanes 5 and 6). Two concentrations of purified
CYP2B6 protein (in femtomoles) and a positive control
(human liver microsome [HLM]) were analyzed at the
same time.
Fig 4. Relationship between efavirenz area under the
observed plasma concentration–time curve (AUC) on
day 10 and hepatic CYP3A4 induction on day 11 (day
11/day 1 erythromycin breath test [ERMBT] ratio).
Individual nontransformed data for the 200-mg efa-
virenz group (circles) and the 400-mg efavirenz group
(squares) are presented (r  0.51 and P  .04 for both
treatment groups combined).
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relations between enterocyte content of CYP3A4 or
P-glycoprotein and systemic exposure of efavirenz. We
and other researchers have used the same immunoblot-
ting techniques to successfully detect such correlations
for other CYP3A4 and P-glycoprotein substrates.12,14,17
However, we were unable to find correlations between
enterocyte levels of CYP3A4 or P-glycoprotein and
parameters of systemic exposure to efavirenz.
In contrast to the substantial liver induction ob-
served, there was no evidence for induction of intestinal
CYP3A4 or intestinal P-glycoprotein in our subjects.
This was unexpected because hPXR is present in both
liver and intestine.6,7 One possibility is that the in-
creased activity of liver CYP3A4 observed resulted
from posttranscriptional modification or activation of
the hepatic enzyme and that the same phenomenon,
which might not be detected by our protein measure-
ments, could be occurring in the intestine. However,
increases in P450 activity on this basis are unusual
(with only 1 example in vivo in any species to our
knowledge18), and efavirenz causes induction of
CYP3A immunoreactive protein in animal liver
(Bristol-Myers Squibb, unpublished data, July 2000). It
is also possible that some induction of CYP3A4 and
P-glycoprotein occurred in the intestine but was below
our level of detection. However, we have previously
used this same Western blot technique to demonstrate
significant induction of intestinal CYP3A4 and
P-glycoprotein (but not the closely related CYP3A5) in
5 adults treated with rifampin for just 2 days.19 In
addition, the 95% CI values for the day 10/day 1 ratios
of enterocyte contents of CYP3A4 and P-glycoprotein
were essentially identical for both treatments and pla-
cebo. In the high-dose group, the highest induction of
either protein that would fall within the 95% CI is 25%
above baseline (ie, greater than 25% induction was
excluded with 95% confidence). It should also be noted
that other investigators have concluded that the magni-
tude of intestinal CYP3A4 induction is greater than
liver induction after oral administration of rifampin.20 It
therefore seems to be likely that efavirenz produced
essentially liver-specific induction in our subjects.
The basis for discrepancy between intestine and liver
responsiveness to induction is unclear, but we speculate
that it may be related to a relatively short duration of
exposure of the enterocyte to efavirenz during oral
administration. The drug has a relatively fast absorption
(tmax of 2 to 3 hours), it is given just once each day, and
the parent drug does not appear to undergo biliary
excretion.9,21 Therefore the total duration of exposure
of the enterocyte to parent efavirenz during treatment
may be insufficient to cause a significant increase in
gene transcription. Alternatively, the mechanism for
induction of hepatic CYP3A4 in liver may involve
novel mechanisms not present in the intestine.
We also anticipated that CYP2B6 may be inducible
by efavirenz because CYP2B induction has been ob-
served in animals and CYP2B6 induction can also be
mediated in human liver by PXR.8 However, we failed
to detect any CYP2B6 in the small intestinal homoge-
nates, either before or after efavirenz treatment (Fig 3).
Because there is currently no validated probe for liver
CYP2B6 activity, we could not determine whether efa-
virenz induced CYP2B6 in the livers of our subjects.
It should be noted that the relative enterocyte con-
centrations of CYP3A4 and P-glycoprotein of each
subject remained largely unchanged during the 10-day
interval between intestinal biopsies. We have previ-
ously shown that there is considerable intraindividual
variation in enterocyte content of CYP3A4 in subjects
maintained for 5 days on a fruit- and vegetable-free
diet12,15 and that dramatic falls in enterocyte CYP3A4
occur when subjects drink even a single glass of grape-
fruit juice.12,22 This has raised the concern that entero-
cyte CYP3A4 levels may be so exquisitely sensitive to
diet that certain studies may require inpatient hospital-
ization and strict dietary control. Our observations in
the current study suggest that volunteers allowed to
maintain their usual dietary habits as outpatients may
have relatively little intrasubject variation in enterocyte
levels of CYP3A4 and P-glycoprotein. Consistent with
this conclusion is the observation that the magnitude of
interaction between grapefruit juice and felodipine,
which varies markedly between subjects and correlates
with enterocyte CYP3A4 content,12 remained relatively
constant within subjects over several weeks in an out-
patient setting.23
It is now well established that the best therapeutic
strategy to treat HIV-1 infection is to combine agents
with different mechanisms of action and with different
dose-limiting toxicities. Such “highly active” combina-
tion therapy can increase the potential for marked drug-
drug interactions to occur because most of the thera-
peutic agents used are substrates or modulators of liver
and intestinal CYP3A4 and P-glycoprotein.24-26 The
observation that efavirenz induces CYP3A4 primarily
in the liver may mean that its potential to reduce sys-
temic exposure to high first-pass drugs is less than other
inducers, such as rifampin, that induce in both the liver
and the intestine.17
In conclusion, efavirenz is an inducer of liver
CYP3A4 and the magnitude of induction appears to be
a function of dose, duration of treatment, and systemic
exposure to parent drug. The ability to serially follow
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hepatic CYP3A4 induction at multiple time points rep-
resents one useful aspect of the ERMBT. However,
efavirenz does not appear to induce intestinal CYP3A4
and P-glycoprotein, and we speculate that this may
reflect a limited duration of exposure of the enterocyte
to efavirenz.
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